DDInter1397 DDInter1615
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration. Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and late-phase CINV during the first 120 hours post-chemotherapy.
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rolapitant
Paroxetine {u} (Compound) binds {v} (Gene) CHRM2
CHRM2 {u} (Gene) is bound by {v} (Compound) Doxepin
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Paroxetine {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rolapitant
Paroxetine {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Iloperidone
Iloperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Paroxetine {u} (Compound) binds {v} (Gene) CHRM2
CHRM2 {u} (Gene) is bound by {v} (Compound) Thioridazine
Thioridazine {u} may lead to a major life threatening interaction when taken with {v} Rolapitant
Paroxetine {u} (Compound) causes {v} (Side Effect) Accommodation disorder
Accommodation disorder {u} (Side Effect) is caused by {v} (Compound) Carbamazepine
Carbamazepine {u} may lead to a major life threatening interaction when taken with {v} Rolapitant
Paroxetine {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rolapitant
Paroxetine {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is downregulated by {v} (Compound) Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Paroxetine {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Paroxetine {u} (Compound) downregulates {v} (Gene) CCNB2
CCNB2 {u} (Gene) is downregulated by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rolapitant
Paroxetine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Paroxetine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Paroxetine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Paroxetine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Iloperidone (Compound) and Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Paroxetine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Thioridazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Rolapitant
Paroxetine (Compound) causes Accommodation disorder (Side Effect) and Accommodation disorder (Side Effect) is caused by Carbamazepine (Compound) and Carbamazepine may lead to a major life threatening interaction when taken with Rolapitant
Paroxetine (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Paroxetine (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Paclitaxel (Compound) and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Paroxetine (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Paroxetine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Rolapitant